Trial doses
Trial- Dose
- 30–60 mcg/kg
- How often
- Single dose, or 2–3 doses weekly or every 2 weeks
- How long
- Up to 49 days of follow-up
Teichman 2006 in healthy adults. The authors found 30 or 60 mcg/kg the best tolerated.
Human studiesLong-acting GHRH analog
CJC-1295 with DAC
DAC:GRF
- Common dose
- 1 mg weekly
- Cycle
- 12 weeks on, 4 off
- Vial sizes
- 5 mg
- Typical draw
- 40 units5 mg with 2 mL, 1 mg
A GRF 1-29 analog with a linker that binds albumin in the blood, stretching its half-life to about 6–8 days. One injection raises GH and IGF-1 for a week or more.
Evidence. Two placebo-controlled dose studies and a single-dose study in healthy adults (2006). A Phase 2 trial in people with HIV was stopped in 2006 and never published. Never approved.
Status
- Approval
- Not approved as a drug in the US or EU. Its developer, ConjuChem, halted a Phase 2 trial in July 2006.
- US compounding
- Nomination withdrawn, so no longer in FDA Category 2 (April 2026). In December 2024 FDA’s advisory committee voted 0 to 13 against adding CJC-1295 with DAC to the 503A bulks list. Not on the July 2026 agenda.
- Sport (WADA 2026)
- Banned in sportS2.2.4 growth hormone releasing factors: GHRH and its analogues, with CJC-1295 named. Banned at all times.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026.
Protocol
Trial
Teichman 2006
Single ascending doses raised GH 2–10× for 6+ days and IGF-1 for 9–11 days. 30 and 60 mcg/kg were the best tolerated.
Community
0.5–2 mg per week, usually 1 mg once weekly.
- Frequency
- Once weekly
- Route
- Subcutaneous injection
- Cycle
- 8–12 weeks on, 4–6 weeks off.
12 weeks on, 4 off, shown over 26 weeks
Common protocols
The ways CJC-1295 with DAC is most often run, each tagged with where it comes from.
Weekly
Community- Dose
- 1 mg (range 0.5–2 mg)
- How often
- Once weekly
- How long
- 8–12 weeks, then 4–6 off
Most cited community schedule. Flat doses like this were never tested in trials.
Draw 40 units5 mg + 2 mL
Dosing by body weight
Trial30–60 mcg/kg. Teichman 2006, healthy adults, single or repeat doses weekly or every 2 weeks. Four single-dose levels were tested; 30 or 60 were best tolerated.
At 70 kg, per dose2.1 mg–4.2 mg0.84–1.68 mL at 5 mg + 2 mL
Levels over time
How much of the drug is in the body week by week, worked out from its trial half-life of about 7 days. It shows the build-up to a steady level and the fall after the last dose.
On the same dose every week, levels reach about 90% of steady state after 4 doses. After the last dose, about 50% is left a week later, and levels fall below 5% after about 5 weeks.
Show the numbers
| Week | Dose that week | Average level that week |
|---|---|---|
| 1 | 1 mg | 50% |
| 2 | 1 mg | 75% |
| 3 | 1 mg | 88% |
| 4 | 1 mg | 94% |
| 5 | 1 mg | 97% |
| 6 | 1 mg | 98% |
| 7 | 1 mg | 99% |
| 8 | 1 mg | 100% |
| 9 | 1 mg | 100% |
| 10 | 1 mg | 100% |
| 11 | 1 mg | 100% |
| 12 | 1 mg | 100% |
| 13 | 1 mg | 100% |
| 14 | 1 mg | 100% |
| 15 | 1 mg | 100% |
| 16 | 1 mg | 100% |
| 17 | – | 50% |
| 18 | – | 25% |
| 19 | – | 12% |
| 20 | – | 6% |
| 21 | – | 3% |
A simple model: each point is the average level over one week, so it leaves out the rise and dip within the week, and it uses one average half-life, so real levels vary from person to person. 100% is the steady weekly average on the final dose shown. Half-life from published trials.
Taking it
Where it goes
Subcutaneous injection once a week, rotating sites. The trials gave it under the skin in healthy adults.
If you miss a dose
No published guidance. With a half-life of about 6–8 days, a dose taken a day or two late changes little. Don’t take two doses close together.
What to expect
- Days 1–6+
One shot raised GH 2–10× (higher with bigger doses) for 6 days or more.
Trial - Days 1–11
IGF-1 rose 1.5–3× and stayed up for 9–11 days after one shot.
Trial - Weeks 1–4
With 2–3 repeat doses, IGF-1 stayed above baseline for up to 28 days, showing a cumulative effect.
Trial
Side effects and what to do
Injection-site pain, swelling or hardness, sometimes hives at the site (most common in trials)
Usually transient. Rotate sites; stop if hives spread.
Headache, flushing, nausea or a flu-like feeling
Reported in trials. Can last days because the drug clears slowly.
Water retention and joint aches
From sustained GH and IGF-1. Lower the dose or stop if it persists.
Higher blood sugar
Check fasting glucose, especially with prediabetes or diabetes.
Stop and get medical help
Chest pain or pressure, trouble breathing, fainting, or hives with face or throat swelling: get emergency care. Effects can last a week after a dose.
Tracking and pairing
Worth tracking
- IGF-1
- Fasting glucose
- Swelling, joint pain or hand numbness
Often paired with
Usually run on its own.
Human studies
3 key published human studies, with how many people took part. Animal studies aren’t listed here.
-
Single doses raised GH 2- to 10-fold for 6 or more days and IGF-1 1.5- to 3-fold for 9 to 11 days; no serious adverse reactions.
- Design
- Two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61
- Dose
- Single doses, or 2 to 3 weekly or every-other-week subcutaneous doses; 30 or 60 mcg/kg best tolerated
- Length
- 28 and 49 days
Teichman et al., J Clin Endocrinol Metab 2006, PMID 16352683
-
GH pulses were preserved; trough GH rose 7.5-fold, mean GH 46% and IGF-1 45%, with no difference between the two doses.
- Design
- Single-dose study of overnight GH pulses in healthy men aged 20 to 40
- Dose
- 60 or 90 mcg/kg subcutaneous, once
- Length
- 1 week
Ionescu and Frohman, J Clin Endocrinol Metab 2006, PMID 17018654
-
Five serum protein spots changed, including lower apolipoprotein A1 and transthyretin isoforms; exploratory biomarker work only.
- Design
- Serum protein study in a subset of men from the 2006 GH-pulse study
- Dose
- 60 to 90 mcg/kg subcutaneous, once
- Length
- 1 week
Sackmann-Sala et al., Growth Horm IGF Res 2009, PMID 19386527
Mixing your vial
| Vial | Water | Common dose | Draw | Strength | Action |
|---|---|---|---|---|---|
| 5 mg | 2 mL | 1 mg | 40 units (0.40 mL) | 2.5 mg/mL |
Dose chart
5 mg vialSyringe units for common doses at different water volumes. Select a cell to open it in the calculator.
| Dose | Water added | ||
|---|---|---|---|
| 1 mL | 2 mL | 3 mL | |
| 0.5 mg | |||
| 0.6 mg | |||
| 0.75 mg | |||
| 1 mg | |||
| 1.5 mg | |||
| 2 mg | |||
U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.
Datasheet
- Half-life
- about 6 to 8 days TrialEstimated at 5.8 to 8.1 days after subcutaneous doses in healthy adults; the DAC group binds blood albumin.
- Type
- Peptide, 30 amino acids
- Molecular weight
- 3,647.2 g/mol
- Formula
- C165H269N47O46
- Sequence
- Y-(D-Ala)-DAIFTQSYRKVLAQLSARKLLQDILSR-K(maleimidopropionyl)-NH2
- Storage before use
- Freezer (−20 °C) for long-term storage; fridge for short periods.
- After mixing or opening
- Fridge (2–8 °C); use within about 4 weeks.
- Half-life: Teichman et al., J Clin Endocrinol Metab 2006, PMID 16352683
- Molecule: PubChem CID 91971820
- Storage: Community Common practice; no approved label exists for this peptide
Cautions
- Side effects last for days because it clears slowly.
- Water retention, flushing and headache.
- Not approved. Its developer halted a Phase 2 trial in July 2006 after a patient died; at the time the cause and any link to the drug were under investigation, and no results were published.
Questions
What is CJC-1295 with DAC?
A GRF 1-29 analog with a linker that binds albumin in the blood, stretching its half-life to about 6–8 days. One injection raises GH and IGF-1 for a week or more.
Is CJC-1295 with DAC FDA-approved?
Not approved as a drug in the US or EU. Its developer, ConjuChem, halted a Phase 2 trial in July 2006. Nomination withdrawn, so no longer in FDA Category 2 (April 2026). In December 2024 FDA’s advisory committee voted 0 to 13 against adding CJC-1295 with DAC to the 503A bulks list. Not on the July 2026 agenda.
What is the usual CJC-1295 with DAC dose?
From human studies (Teichman 2006): Single ascending doses raised GH 2–10× for 6+ days and IGF-1 for 9–11 days. 30 and 60 mcg/kg were the best tolerated. From community reports, not established: 0.5–2 mg per week, usually 1 mg once weekly. These are the amounts sources reference, not recommendations.
How much water do I mix CJC-1295 with DAC with?
There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 5 mg vial, the strength is 2.5 mg/mL, so 1 mg is 40 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.
What is the half-life of CJC-1295 with DAC?
About 6 to 8 days, measured in human studies. Estimated at 5.8 to 8.1 days after subcutaneous doses in healthy adults; the DAC group binds blood albumin.
How should CJC-1295 with DAC be stored?
Before mixing: Freezer (−20 °C) for long-term storage; fridge for short periods. After mixing: Fridge (2–8 °C); use within about 4 weeks. This is common practice; no product label covers it.
Is CJC-1295 with DAC banned in sport?
Yes. S2.2.4 growth hormone releasing factors: GHRH and its analogues, with CJC-1295 named. Banned at all times.
Has CJC-1295 with DAC been studied in people?
Yes. The human studies section lists 3 published studies. Among them, from 2006: Single doses raised GH 2- to 10-fold for 6 or more days and IGF-1 1.5- to 3-fold for 9 to 11 days; no serious adverse reactions.
Sources
- Teichman et al., CJC-1295 in healthy adults (JCEM 2006)
- Ionescu & Frohman, GH pulses during CJC-1295 (JCEM 2006)
- Lipodystrophy study halted after patient death (aidsmap, 2006)
For the protocol details
- Teichman et al., CJC-1295 in healthy adults (JCEM 2006, abstract)
- LaValle, CJC-1295 presentation, FDA docket FDA-2024-N-4777
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.